RedHill Biopharma (RDHL) Raw Materials (2018 - 2024)

RedHill Biopharma (RDHL) has reported Raw Materials for 7 consecutive years, with $513000.0 the latest figure, recorded in Q4 2024.

• On a quarterly basis, Raw Materials fell 38.04% year-over-year to $513000.0 in Q4 2024; TTM through Dec 2024 was $513000.0, a 38.04% decrease from a year earlier, with the FY2024 full-year figure at $513000.0, down 38.04% from the prior year.
• Raw Materials was $513000.0 for Q4 2024 at RedHill Biopharma, down from $828000.0 in the prior quarter.
• Over five years, Raw Materials peaked at $3.0 million in Q4 2021 and troughed at $513000.0 in Q4 2024.
• A 5-year average of $1.6 million and a median of $1.8 million in 2020 frame the typical range for Raw Materials.
• Across the five-year window, Raw Materials soared 68.08% in 2021 and plunged 53.92% in 2023, its largest moves.
• Over 5 years, Raw Materials stood at $1.8 million in 2020, then soared by 68.08% to $3.0 million in 2021, then slumped by 40.34% to $1.8 million in 2022, then slumped by 53.92% to $828000.0 in 2023, then tumbled by 38.04% to $513000.0 in 2024.
• The last three Raw Materials figures came in at $513000.0 (Q4 2024), $828000.0 (Q4 2023), and $1.8 million (Q4 2022), per Business Quant data.